3/27
06:54 am
dtil
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/27
06:45 am
dtil
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Low
Report
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/20
04:39 pm
dtil
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 [Yahoo! Finance]
Low
Report
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 [Yahoo! Finance]
3/20
04:30 pm
dtil
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
Low
Report
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
3/19
07:06 am
dtil
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy [Yahoo! Finance]
Neutral
Report
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy [Yahoo! Finance]
3/19
07:00 am
dtil
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
Low
Report
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
3/6
08:58 am
dtil
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency [Yahoo! Finance]
Low
Report
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency [Yahoo! Finance]
3/6
08:45 am
dtil
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
Low
Report
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
3/6
08:25 am
dtil
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506 [Yahoo! Finance]
Low
Report
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506 [Yahoo! Finance]
3/6
08:00 am
dtil
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506
Low
Report
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506
3/1
07:02 am
dtil
Precision BioSciences stock falls after pricing $40M securities offering [Seeking Alpha]
High
Report
Precision BioSciences stock falls after pricing $40M securities offering [Seeking Alpha]
3/1
06:47 am
dtil
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants [Yahoo! Finance]
High
Report
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants [Yahoo! Finance]
3/1
06:30 am
dtil
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
High
Report
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
2/29
04:13 pm
dtil
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants [Yahoo! Finance]
High
Report
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants [Yahoo! Finance]
2/29
04:01 pm
dtil
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
High
Report
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
2/27
06:08 am
dtil
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength? [Yahoo! Finance]
Low
Report
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength? [Yahoo! Finance]
2/20
07:00 am
dtil
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
High
Report
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
2/13
07:11 am
dtil
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations [Yahoo! Finance]
Medium
Report
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations [Yahoo! Finance]
2/13
07:00 am
dtil
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
Medium
Report
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
2/12
07:00 am
dtil
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
Medium
Report
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
2/9
07:15 am
dtil
Precision BioSciences to Effect a Reverse Stock Split [Yahoo! Finance]
Low
Report
Precision BioSciences to Effect a Reverse Stock Split [Yahoo! Finance]
2/9
07:00 am
dtil
Precision BioSciences to Effect a Reverse Stock Split
Low
Report
Precision BioSciences to Effect a Reverse Stock Split
2/8
10:18 am
dtil
Global CRISPR Genomic Cure Market Set to Soar with 29.21% CAGR till 2028, Driven by Tech Advancements and Therapeutic Expansion [Yahoo! Finance]
Low
Report
Global CRISPR Genomic Cure Market Set to Soar with 29.21% CAGR till 2028, Driven by Tech Advancements and Therapeutic Expansion [Yahoo! Finance]
1/9
07:13 am
dtil
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases [Yahoo! Finance]
Medium
Report
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases [Yahoo! Finance]
1/9
07:13 am
dtil
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases [Yahoo! Finance]
Low
Report
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases [Yahoo! Finance]